|
CLINICAL PIPELINE
Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. In addition to Remoxy™, a unique, abuse-resistant controlled-release oxycodone, the Company has three drug candidates in clinical programs, including a novel radio-labeled monoclonal antibody to treat metastatic melanoma, as well as PTI-202 and PTI-721. Pain Therapeutics is also working on a new treatment for patients with hemophilia.
PIPELINE STATUS
| Drug Candidate |
Indication |
Phase |
Commercial Rights |
| Remoxy |
Moderate/severe chronic pain |
III |
King Pharmaceuticals |
| PTI-202 |
Moderate/severe chronic pain |
I |
King Pharmaceuticals |
| PTI-721 |
Moderate/severe chronic pain |
I |
King Pharmaceuticals |
| Monoclonal Antibody |
Metastatic melanoma |
I |
Pain Therapeutics, Inc. |
| Factor IX Replacement |
Hemophilia |
Pre-clinical |
Pain Therapeutics, Inc. |
|
|
